Jessica N Kuzma1, Gail Cromer2, Derek K Hagman2, Kara L Breymeyer3, Christian L Roth4, Karen E Foster-Schubert5, Sarah E Holte2, David S Weigle5, Mario Kratz6. 1. Cancer Prevention Program, Division of Public Health Sciences, and Departments of Epidemiology and. 2. Cancer Prevention Program, Division of Public Health Sciences, and. 3. Prevention Center, Fred Hutchinson Cancer Research Center, Seattle, WA; and. 4. Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA. 5. Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, and. 6. Cancer Prevention Program, Division of Public Health Sciences, and Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, and Departments of Epidemiology and mkratz@fredhutch.org.
Abstract
BACKGROUND:Sugar-sweetened beverage (SSB) consumption and low-grade chronic inflammation are both independently associated with type 2 diabetes and cardiovascular disease. Fructose, a major component of SSBs, may acutely trigger inflammation, which may be one link between SSB consumption and cardiometabolic disease. OBJECTIVE: We sought to determine whether beverages sweetened with fructose, high-fructose corn syrup (HFCS), and glucose differentially influence systemic inflammation [fasting plasma C-reactive protein and interleukin-6 (IL-6) as primary endpoints] acutely and before major changes in body weight. Secondary endpoints included adipose tissue inflammation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose intake and low-grade inflammation. DESIGN: We conducted a randomized, controlled, double-blind, crossover design dietary intervention (the Diet and Systemic Inflammation Study) in 24 normal-weight to obese adults without fructose malabsorption. Participants drank 4 servings/d of fructose-, glucose-, or HFCS-sweetened beverages accounting for 25% of estimated calorie requirements while consuming a standardized diet ad libitum for three 8-d periods. RESULTS: Subjects consumed 116% of their estimated calorie requirement while drinking the beverages with no difference in total energy intake or body weight between groups as reported previously. Fasting plasma concentrations of C-reactive protein and IL-6 did not differ significantly at the end of the 3 diet periods. We did not detect a consistent differential effect of the diets on measures of adipose tissue inflammation except for adiponectin gene expression in adipose tissue (P = 0.005), which was lowest after the glucose phase. We also did not detect consistent evidence of a differential impact of these sugars on measures of intestinal permeability (lactulose:mannitol test, plasma zonulin, and plasma lipopolysaccharide-binding protein). CONCLUSION: Excessive amounts of fructose, HFCS, and glucose from SSBs consumed over 8 d did not differentially affect low-grade chronic systemic inflammation in normal-weight to obese adults. This trial was registered at clinicaltrials.gov as NCT01424306.
RCT Entities:
BACKGROUND: Sugar-sweetened beverage (SSB) consumption and low-grade chronic inflammation are both independently associated with type 2 diabetes and cardiovascular disease. Fructose, a major component of SSBs, may acutely trigger inflammation, which may be one link between SSB consumption and cardiometabolic disease. OBJECTIVE: We sought to determine whether beverages sweetened with fructose, high-fructose corn syrup (HFCS), and glucose differentially influence systemic inflammation [fasting plasma C-reactive protein and interleukin-6 (IL-6) as primary endpoints] acutely and before major changes in body weight. Secondary endpoints included adipose tissue inflammation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose intake and low-grade inflammation. DESIGN: We conducted a randomized, controlled, double-blind, crossover design dietary intervention (the Diet and Systemic Inflammation Study) in 24 normal-weight to obese adults without fructose malabsorption. Participants drank 4 servings/d of fructose-, glucose-, or HFCS-sweetened beverages accounting for 25% of estimated calorie requirements while consuming a standardized diet ad libitum for three 8-d periods. RESULTS: Subjects consumed 116% of their estimated calorie requirement while drinking the beverages with no difference in total energy intake or body weight between groups as reported previously. Fasting plasma concentrations of C-reactive protein and IL-6 did not differ significantly at the end of the 3 diet periods. We did not detect a consistent differential effect of the diets on measures of adipose tissue inflammation except for adiponectin gene expression in adipose tissue (P = 0.005), which was lowest after the glucose phase. We also did not detect consistent evidence of a differential impact of these sugars on measures of intestinal permeability (lactulose:mannitol test, plasma zonulin, and plasma lipopolysaccharide-binding protein). CONCLUSION: Excessive amounts of fructose, HFCS, and glucose from SSBs consumed over 8 d did not differentially affect low-grade chronic systemic inflammation in normal-weight to obese adults. This trial was registered at clinicaltrials.gov as NCT01424306.
Authors: Matthias B Schulze; Kurt Hoffmann; JoAnn E Manson; Walter C Willett; James B Meigs; Cornelia Weikert; Christin Heidemann; Graham A Colditz; Frank B Hu Journal: Am J Clin Nutr Date: 2005-09 Impact factor: 7.045
Authors: Isabelle Aeberli; Philipp A Gerber; Michel Hochuli; Sibylle Kohler; Sarah R Haile; Ioanna Gouni-Berthold; Heiner K Berthold; Giatgen A Spinas; Kaspar Berneis Journal: Am J Clin Nutr Date: 2011-06-15 Impact factor: 7.045
Authors: Mattias Ekström; Martin Halle; Staffan Bjessmo; Jan Liska; Maria Kolak; Rachel Fisher; Per Eriksson; Per Tornvall Journal: Am J Physiol Endocrinol Metab Date: 2010-05-18 Impact factor: 4.310
Authors: I Shimomura; T Funahashi; M Takahashi; K Maeda; K Kotani; T Nakamura; S Yamashita; M Miura; Y Fukuda; K Takemura; K Tokunaga; Y Matsuzawa Journal: Nat Med Date: 1996-07 Impact factor: 53.440
Authors: Teresa T Fung; Vasanti Malik; Kathryn M Rexrode; JoAnn E Manson; Walter C Willett; Frank B Hu Journal: Am J Clin Nutr Date: 2009-02-11 Impact factor: 7.045
Authors: Huicui Meng; Nirupa R Matthan; Susan K Fried; Silvia Berciano; Maura E Walker; Jean M Galluccio; Alice H Lichtenstein Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Nicola M McKeown; Hassan S Dashti; Jiantao Ma; Danielle E Haslam; Jessica C Kiefte-de Jong; Caren E Smith; Toshiko Tanaka; Mariaelisa Graff; Rozenn N Lemaitre; Denis Rybin; Emily Sonestedt; Alexis C Frazier-Wood; Dennis O Mook-Kanamori; Yanping Li; Carol A Wang; Elisabeth T M Leermakers; Vera Mikkilä; Kristin L Young; Kenneth J Mukamal; L Adrienne Cupples; Christina-Alexandra Schulz; Tzu-An Chen; Ruifang Li-Gao; Tao Huang; Wendy H Oddy; Olli Raitakari; Kenneth Rice; James B Meigs; Ulrika Ericson; Lyn M Steffen; Frits R Rosendaal; Albert Hofman; Mika Kähönen; Bruce M Psaty; Louise Brunkwall; Andre G Uitterlinden; Jorma Viikari; David S Siscovick; Ilkka Seppälä; Kari E North; Dariush Mozaffarian; Josée Dupuis; Marju Orho-Melander; Stephen S Rich; Renée de Mutsert; Lu Qi; Craig E Pennell; Oscar H Franco; Terho Lehtimäki; Mark A Herman Journal: Diabetologia Date: 2017-11-02 Impact factor: 10.460
Authors: Jessica N Kuzma; Gail Cromer; Derek K Hagman; Kara L Breymeyer; Christian L Roth; Karen E Foster-Schubert; Sarah E Holte; David S Weigle; Mario Kratz Journal: Eur J Clin Nutr Date: 2018-08-30 Impact factor: 4.016